EXHIBIT 99.1
| Contact: | Harriss T. Currie | |
| Vice President, Finance and Chief Financial Officer | ||
| 512-219-8020 | ||
| hcurrie@luminexcorp.com |
LUMINEX CORPORATION REPORTS SECOND QUARTER 2007 RESULTS
AUSTIN, Texas (July 25, 2007) — Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter and six months ended June 30, 2007. Financial and operating highlights include the following:
| • | Consolidated total revenue of $17.5 million, a 32 percent increase year-over-year | ||
| • | System shipments surpass 4,500, up 20 percent from a year ago | ||
| • | Consolidated gross margin of 59 percent | ||
| • | Announced a distribution agreement with Exiqon for the FlexmiR™ line of products co-developed by the companies in 2006 | ||
| • | Unveiled FlexMAP 3D™, a next generation bead-based multiplexing system | ||
| • | Completion of manufacturing space update/expansion in response to expanded product offerings | ||
| • | Partner successes, including Bio-Rad BioPlex 2200 Quest deal | ||
| • | Named Doug Bryant as Executive Vice President and Chief Operating Officer |
Consolidated revenue for the second quarter of 2007 was $17.5 million compared with $13.3 million in the second quarter of 2006. Consolidated net loss for the second quarter of 2007 was $3.2 million, or $0.09 per share, as compared with net income of $271,000, or $0.01 per share, for the comparable period of 2006.
On March 1, 2007, Luminex completed the acquisition of Tm Bioscience Corporation, a leader in the commercial genetic testing market. Beginning with the first quarter of 2007, Luminex reported the following segments: Technology Group and Assay Group. The Technology Group consists of system sales to partners, raw bead sales, royalties, service and support of the core technology and other miscellaneous items. The Assay Group consists of the Luminex Bioscience Group, or LBG, and the acquired Tm Bioscience operations, now known as Luminex Molecular Diagnostics, or LMD. This segment is primarily involved in the development and sale of assays on xMAP® technology for use on the Company’s installed base of systems.
The Assay Group results for the second quarter of 2007 include three months of revenue from LBG and from LMD. Assay Group results for 2006 consist of LBG only. LBG introduced its first two products in the fourth quarter of 2006.
-MORE-
LMNX Reports Second Quarter 2007 Results
Page 2
July 25, 2007
Page 2
July 25, 2007
LUMINEX CORPORATION
REPORTABLE SEGMENT HIGHLIGHTS
(unaudited)
(in thousands)
REPORTABLE SEGMENT HIGHLIGHTS
(unaudited)
(in thousands)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
| Revenue | ||||||||||||||||
| Technology group | $ | 14,822 | $ | 13,254 | $ | 30,560 | $ | 26,251 | ||||||||
| Assay group | 4,000 | 14 | 5,200 | 14 | ||||||||||||
| Eliminations of intersegment revenue | (1,274 | ) | — | (1,605 | ) | — | ||||||||||
| Total revenue | 17,548 | 13,268 | 34,155 | 26,265 | ||||||||||||
| Operating income (loss) | ||||||||||||||||
| Technology group | (408 | ) | 231 | 740 | 786 | |||||||||||
| Assay group | (2,623 | ) | (498 | ) | (4,078 | ) | (940 | ) | ||||||||
| Eliminations of intersegment operating income | (354 | ) | — | (419 | ) | — | ||||||||||
| Operating income (loss) | (3,385 | ) | (267 | ) | (3,757 | ) | (154 | ) | ||||||||
“The results for the second quarter of 2007 reflect continued quarterly revenue growth and a solid performance for Luminex,” said Patrick J. Balthrop, president and chief executive officer of Luminex. “Our xMAP platform continues to build critical mass across many segments of the life sciences marketplace. We surpassed another milestone with over 4,500 Luminex systems placed in research laboratories, clinical laboratories, bio-defense facilities and academic institutions around the world at the end of the second quarter. With our proprietary technologies, growing installed base of instruments and expanding distribution channels through our strategic partnerships, we have the opportunity to leverage these assets and achieve further market penetration in 2007.
“We are pleased with our continued progress in the integration of LMD into our operations,” added Balthrop. “Our integration process is on track and we expect to deliver over $5 million in annual synergies from the combined companies. With our additional internal assay capabilities, we have several exciting opportunities to further capitalize on the growing molecular diagnostics market. We also continued to make strategic investments in our research efforts and, as a result, made significant progress in assay product development through LBG. With the addition of Doug Bryant to our management team as chief operating officer, we have further enhanced our leadership team to execute our strategy in these key areas and expand our market reach.”
CONFERENCE CALL
Management will host a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2007, on Thursday, July 26, 2007, at 8:00 a.m. Eastern time. The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at our website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software.
-MORE-
LMNX Reports Second Quarter 2007 Results
Page 3
July 25, 2007
Page 3
July 25, 2007
If you are unable to participate during the live webcast, the call and slides will be archived for one year on the website using the ‘replay’ link.
ABOUT LUMINEX CORPORATION
Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP® technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP® can be obtained on the Internet at http://www.luminexcorp.com.
Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products, the Company’s dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company’s revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company’s strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, including Tm Bioscience Corporation, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
-MORE-
LMNX Reports Second Quarter 2007 Results
Page 4
July 25, 2007
Page 4
July 25, 2007
LUMINEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
| June 30, | December 31, | |||||||
| 2007 | 2006 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,836 | $ | 27,414 | ||||
| Short-term investments | 3,314 | 10,956 | ||||||
| Accounts receivable, net | 11,614 | 8,237 | ||||||
| Inventory, net | 7,100 | 4,571 | ||||||
| Other | 1,874 | 1,917 | ||||||
| Total current assets | 35,738 | 53,095 | ||||||
| Property and equipment, net | 10,189 | 4,985 | ||||||
| Intangible assets, net | 2,142 | — | ||||||
| Long-term investments | 5,311 | 7,346 | ||||||
| Goodwill | 65,432 | (1) | — | |||||
| Other | 1,705 | 1,270 | ||||||
| Total assets | $ | 120,517 | $ | 66,696 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,687 | $ | 3,255 | ||||
| Accrued liabilities | 8,219 | 2,905 | ||||||
| Deferred revenue and other | 3,073 | 2,756 | ||||||
| Total current liabilities | 14,979 | 8,916 | ||||||
| Long-term debt | 3,825 | — | ||||||
| Deferred revenue and other | 3,814 | 3,621 | ||||||
| Total liabilities | 22,618 | 12,537 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 35 | 32 | ||||||
| Additional paid-in capital | 186,059 | 139,116 | ||||||
| Accumulated other comprehensive gain | (80 | ) | 65 | |||||
| Accumulated deficit | (88,115 | ) | (85,054 | ) | ||||
| Total stockholders’ equity | 97,899 | 54,159 | ||||||
| Total liabilities and stockholders’ equity | $ | 120,517 | $ | 66,696 | ||||
(1) Luminex has recorded $65.4 million of goodwill related to the Tm Bioscience acquisition. This goodwill asset is subject to adjustment as Luminex completes certain standard activities around the transaction such as: recording of final transaction related costs and allocation of the purchase price based on our final determination of the fair market value of the acquired operation’s assets and liabilities. No assurances can be given as to the size of any subsequent goodwill adjustment, if any, at this time. Luminex anticipates it will complete the purchase price allocations during the third quarter of 2007 and a portion of the goodwill balance will be allocated to the identified intangible assets at that time.
LMNX Reports Second Quarter 2007 Results
Page 5
July 25, 2007
Page 5
July 25, 2007
LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Revenue | $ | 17,548 | $ | 13,268 | $ | 34,155 | $ | 26,265 | ||||||||
| Cost of revenue | 7,211 | 5,608 | 13,388 | 10,346 | ||||||||||||
| Gross profit | 10,337 | 7,660 | 20,767 | 15,919 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 3,865 | 1,790 | 6,571 | 3,987 | ||||||||||||
| Selling, general and administrative | 9,857 | 6,137 | 17,953 | 12,086 | ||||||||||||
| Total operating expenses | 13,722 | 7,927 | 24,524 | 16,073 | ||||||||||||
| Loss from operations | (3,385 | ) | (267 | ) | (3,757 | ) | (154 | ) | ||||||||
| Interest expense from long-term debt | (334 | ) | — | (419 | ) | — | ||||||||||
| Other income, net | 421 | 551 | 1,028 | 967 | ||||||||||||
| Income taxes | 101 | (13 | ) | 87 | (16 | ) | ||||||||||
| Net income (loss) | $ | (3,197 | ) | $ | 271 | $ | (3,061 | ) | $ | 797 | ||||||
| Net income (loss) per share, basic | $ | (0.09 | ) | $ | 0.01 | $ | (0.09 | ) | $ | 0.03 | ||||||
| Shares used in computing net income (loss) per share, basic | 35,006 | 31,386 | 33,504 | 31,288 | ||||||||||||
| Net income (loss) per share, diluted | $ | (0.09 | ) | $ | 0.01 | $ | (0.09 | ) | $ | 0.02 | ||||||
| Shares used in computing net income (loss) per share, diluted | 35,006 | 32,876 | 33,504 | 32,606 | ||||||||||||
-MORE-
LMNX Reports Second Quarter 2007 Results
Page 6
July 25, 2007
Page 6
July 25, 2007
LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Operating activities: | ||||||||||||||||
| Net income (loss) | $ | (3,197 | ) | $ | 271 | $ | (3,061 | ) | $ | 797 | ||||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||||||||||
| Depreciation and amortization | 978 | 384 | 1,518 | 748 | ||||||||||||
| Stock-based compensation and other | 1,593 | 1,259 | 3,100 | 2,424 | ||||||||||||
| (Gain) loss on disposal of assets | 34 | (2 | ) | 88 | 25 | |||||||||||
| Other | 4 | (7 | ) | 4 | (9 | ) | ||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||
| Accounts receivable, net | (580 | ) | (3,136 | ) | (1,657 | ) | (1,476 | ) | ||||||||
| Inventory, net | (689 | ) | 460 | (721 | ) | 138 | ||||||||||
| Prepaids and other | (460 | ) | (399 | ) | (120 | ) | 29 | |||||||||
| Accounts payable | (2,263 | ) | (254 | ) | (3,817 | ) | (1,506 | ) | ||||||||
| Accrued liabilities | 772 | 335 | (2,353 | ) | (835 | ) | ||||||||||
| Deferred revenue | (217 | ) | 5 | 143 | (225 | ) | ||||||||||
| Net cash provided by (used in) operating activities | (4,025 | ) | (1,084 | ) | (6,876 | ) | 110 | |||||||||
| Investing activities: | ||||||||||||||||
| Net purchases of held-to-maturity investments | 2,185 | 955 | 9,710 | (1,045 | ) | |||||||||||
| Purchase of property and equipment | (1,724 | ) | (643 | ) | (3,329 | ) | (1,528 | ) | ||||||||
| Acquisition of business, net of cash acquired | (744 | ) | — | (2,735 | ) | — | ||||||||||
| Acquired technology rights | (265 | ) | — | (265 | ) | — | ||||||||||
| Proceeds from sale of assets | 30 | 2 | 30 | 7 | ||||||||||||
| Net cash provided by (used in) investing activities | (518 | ) | 314 | 3,411 | (2,566 | ) | ||||||||||
| Financing activities: | ||||||||||||||||
| Payments on debt | (117 | ) | — | (12,345 | ) | — | ||||||||||
| Proceeds from issuance of common stock | 159 | 358 | 174 | 1,434 | ||||||||||||
| Other | 7 | — | 7 | — | ||||||||||||
| Net cash provided by (used in) financing activities | 49 | 358 | (12,164 | ) | 1,434 | |||||||||||
| Effect of foreign currency exchange rate on cash | 135 | 16 | 51 | 22 | ||||||||||||
| Change in cash and cash equivalents | (4,359 | ) | (396 | ) | (15,578 | ) | (1,000 | ) | ||||||||
| Cash and cash equivalents, beginning of period | 16,195 | 24,602 | 27,414 | 25,206 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 11,836 | $ | 24,206 | $ | 11,836 | $ | 24,206 | ||||||||
| Supplemental disclosure of cashflow information: | ||||||||||||||||
| Interest and penalties paid | $ | 254 | $ | — | $ | 1,335 | $ | — | ||||||||
| Supplemental disclosure of non-cash effect of acquisitions: | ||||||||||||||||
| Purchase price | $ | (744 | ) | $ | — | $ | (47,745 | ) | $ | — | ||||||
| Common stock issued | — | — | 41,755 | — | ||||||||||||
| Conversion of Tm options and warrants | — | — | 2,315 | — | ||||||||||||
| Cash acquired | — | — | 940 | — | ||||||||||||
| Acquisition, net of cash acquired | $ | (744 | ) | $ | — | $ | (2,735 | ) | $ | — | ||||||
-MORE-
LMNX Reports Second Quarter 2007 Results
Page 7
July 25, 2007
Page 7
July 25, 2007
SUPPLEMENTAL SCHEDULES (unaudited)
The following table provides a detail of revenue by type for the consolidated Company for the three and six months ended June 30, 2007 and 2006 (in thousands).
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| 2007 | 2006 | 2007 | 2006 | |||||||||||||
| System Revenue | $ | 5,583 | $ | 5,811 | $ | 11,314 | $ | 9,803 | ||||||||
| Consumable Revenue | 3,305 | 3,053 | 8,116 | 8,555 | ||||||||||||
| Royalty Revenue | 2,241 | 2,001 | 4,773 | 3,791 | ||||||||||||
| Reagent Revenue | 3,737 | 14 | 4,881 | 14 | ||||||||||||
| Service Revenue | 1,087 | 811 | 2,090 | 1,618 | ||||||||||||
| Other Miscellaneous Revenue | 1,595 | 1,578 | 2,981 | 2,484 | ||||||||||||
| Total Revenue | $ | 17,548 | $ | 13,268 | $ | 34,155 | $ | 26,265 | ||||||||
-END-